VANCOUVER, June 5 /PRNewswire/ - iCo Therapeutics announced today the
appointment of Dr. Richard W. Barker and William Jarosz to its board of
Dr. Barker is currently Director General of the Association of the
British Pharmaceutical Industry (ABPI). His twenty years of experience
includes a number of senior leadership roles in the UK and abroad and spans
the pharmaceutical, biotechnology and medical informatics sectors.
William Jarosz is currently a Partner in the global investment
management firm Cartesian Capital Group, LLC. He has broad expertise in
international private equity investments, cross-border acquisitions,
capital markets, and corporate and securities laws.
"We are thrilled to have both Dr. Barker and Mr. Jarosz join the
iCoTherapeutics team," said company President and CEO Andrew Rae. "Their
membership on our board adds strategic expertise in numerous capacities
including both the clinical and business aspects of drug development."
Prior to joining the ABPI, Dr. Barker was founder and president of New
Medicine Partners, a consulting firm to pharmaceutical and biotech
enterprises. His past roles include CEO of iKnowMed, a clinical decision
support and pharmaceutical services business in oncology; Chief Executive
of Chiron Diagnostics, General Manager of IBM's Worldwide Healthcare
Solutions division, and leader of McKinsey's European healthcare practice.
"iCoTherapeutics' strategic approach to drug development and
commercialization is novel and sound," said Dr. Barker. "I look forward to
working with the entire iCo team to provide a global perspective towards
helping bring promising new opportunities to the treatment of eye
Dr. Barker is currently a board member of the European Federation of
Pharmaceutical Manufacturers and Associations (EFPIA) and council member of
the international equivalent body (IFPMA). He serves on the board of
Adlyfe, a company specializing in protein misfolding diseases. Dr. Barker
holds a D. Phil in biophysics and a BA in chemistry both from Oxford
University. His research is in biological magnetic resonance at Oxford,
Leeds and Munich.
Prior to helping found Cartesian Capital Group, LLC, Mr. Jarosz served
as Managing Director and General Counsel of AIG Capital Partners, a
subsidiary of American International Group, Inc., and as Managing Director
of the AIG-Brunswick Millennium Fund. While at AIG Capital Partners, Mr.
Jarosz was responsible for various private equity transactions for the
firm's global private equity funds.
Mr.Jarosz practiced law at Debevoise & Plimpton, specializing in
international private equity investment and general corporate and
securities transactions. He also served as a consultant to the World Bank
on the regulation of Foreign Direct Investment in emerging markets. Mr.
Jarosz is a graduate of the University of Montana, and received an MA in
Law and Diplomacy from the Fletcher School at Tufts University and a JD
from Harvard Law School.
iCo Therapeutics Inc. is an emerging, Vancouver-based biotechnology
company focused on developing pre-existing drugs for a range of new
conditions affecting isolated biological environments - areas such as the
eye, spinal cord, or joints - where locally-administered application of
these therapies would have minimal systemic distribution and fewer safety
For more information, visit the company website at:
Business Development Contact: Finance/Investor Contact:
Dr. John Clement, CTO Mr. John Meekison, CFO
Amanda Smith, Principal, Smith Biotech
SOURCE iCo Therapeutics Inc.